fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Budesonide & formoterol fumarate dihydrate

All products: Limited Use (codes 330)

Symbicort 100 Turbuhaler · DIN 02245385 · 100 mcg/6 mcg · dry-powder inhaler, 120 doses

Limited Use, Reason for Use code 330 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 330 required
Write on scriptReason for Use code 330 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Symbicort 100 Turbuhaler · DIN 02245385 Manufacturer: AstraZeneca; listing date 2003-01-30 Health Canada: Marketed since 2002-02-08 · brand SYMBICORT 100 TURBUHALER · ATC R03AK07 FORMOTEROL AND BUDESONIDE · form Powder · route Inhalation · ingredients BUDESONIDE 100 MCG/ACT, FORMOTEROL FUMARATE DIHYDRATE 6 MCG/ACT · company Astrazeneca canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Symbicort 100 Turbuhaler: Formulary list price $79.85 per unit (the source does not state the unit; exact figure $79.8500). What the ministry pays, not the patient.

Ministry pays: $79.8500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245385)

Source record
DIN 02245385: Symbicort 100 Turbuhaler Raw flags: sec12=Y, sec3=Y Item: 121200087; group id 220; item number 0397; lccId 00032; manufacturer id AZC Source form: Pd Inh-120 Dose Pk; strength: 100mcg/6mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $79.8500; ministry $79.8500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245385 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69428
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (R03A, R03AK): coverage varies; not interchangeable

  • Fluticasone furoate + vilanterol (Breo Ellipta): limited Use 330, limited Use 330, 456
  • Formoterol + mometasone furoate (Zenhale): limited Use 330
  • Fluticasone + salmeterol (Advair 125): limited Use 330
  • Salbutamol (Teva-Salbutamol Sterinebs P.F.): general benefit, limited Use 256, 257, 258, 259, limited Use 265, 266, 267, 268, not a benefit
  • Terbutaline (Bricanyl Turbuhaler): general benefit
  • Aclidinium + formoterol (Duaklir Genuair): limited Use 459

8 more in the class list below

Other drugs in the same formulary class (12:12 Sympathomimetic (Adrenergic) Agents) and how they are covered

Matched class: 12:12 Sympathomimetic (Adrenergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE, SALBUTAMOL 12:12 Sympathomimetic (Adrenergic) Agents

FLUTICASONE FUROATE & VILANTEROL

· 2 products · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) · strengths: 100mcg & 25mcg, 200mcg & 25mcg · Blister Pd Inh-30 Dose Pk

MOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg & 5mcg, 200mcg & 5mcg · Metered Dose Inh-120 Dose Pk

SALMETEROL XINAFOATE & FLUTICASONE PROPIONATE

· 11 products · Limited Use, codes 330 · strengths: 25/125mcg/Metered Dose, 25/250mcg/Metered Dose, 50/100mcg, 50/250mcg, 50/500mcg · Inh-120 Dose Pk, Inh-60 Dose Pk

SALBUTAMOL

· 20 products · Limited Use, codes 265, 266, 267, 268 (4), Listed, not a benefit (8), Limited Use, codes 256, 257, 258, 259 (1), General benefit (7) · strengths: 1mg/mL, 2mg/mL, 5mg/mL, 100mcg/Metered Dose, 2mg, 4mg · Inh Sol- 2.5mL Pk, Inh Sol-10mL Pk, Inh-200 dose Pk, Tab

TERBUTALINE SULFATE

· 2 products · General benefit · strengths: 0.5mg/Dose · Inh-100 Dose Pk, Inh-120 Dose Pk

ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 459 · strengths: 400mcg & 12mcg · Metered Dose Pd Inh-60 Dose Pk

BUDESONIDE&GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE)&FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 638 · strengths: 160mcg & 7.2mcg & 5mcg/Act · Metered Dose Inh-120 Dose Pk

FLUTICASONE FUROATE & UMECLIDINIUM BROMIDE & VILANTEROL TRIFENATATE

· 1 products · Limited Use, codes 567 · strengths: 100mcg & 62.5mcg & 25mcg · Pd Inh-30 Dose Pk

FORMOTEROL FUMARATE

· 1 products · Limited Use, codes 132 · strengths: 12mcg/Cap · Inh Pd-Device Pk

FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 132 · strengths: 6mcg/Metered Dose, 12mcg/Metered Dose · Pd Inh-60 Dose Pk

INDACATEROL

· 1 products · Limited Use, codes 443 · strengths: 75mcg · Inh Pd-Cap

INDACATEROL & GLYCOPYRRONIUM

· 1 products · Limited Use, codes 459 · strengths: 110mcg & 50mcg · Inh Pd-Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:12 and 4 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: asthma
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. FLUTICASONE FUROATE & VILANTEROL · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) Page 3 of 74 Asthma BREO ELLIPTA 100/25 mcg and BREO ELLIPTA 200/25 mcg are indicated for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. PM: https://pdf.hres.ca/dpd_pm/00049111.PDF; date January 7, 2019; DIN 02408872; fetched 2026-09-10 Product monograph INDACATEROL ACETATE & MOMETASONE FUROATE · Limited Use, codes 626 1 INDICATIONS ATECTURA BREEZHALER (indacaterol/mometasone furoate) is a combination of a long-acting beta2- adrenergic agonist (LABA) and an inhaled corticosteroid (ICS) indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease. PM: https://pdf.hres.ca/dpd_pm/00063537.PDF; date May 5, 2020; DIN 02498685; fetched 2026-09-10 Product monograph MOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 330 1 Indications ZENHALE® (mometasone furoate / formoterol fumarate dihydrate inhalation aerosol), is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) indicated for: • the treatment of asthma, in patients 12 years of age and older with reversible obstructive airway disease. PM: https://pdf.hres.ca/dpd_pm/00080784.PDF; date 2025-06-09; DIN 02361752; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Asthma SYMBICORT TURBUHALER (budesonide and formoterol fumarate dihydrate) is indicated for the treatment of asthma in patients 12 years and older with reversible obstructive airways disease. SYMBICORT TURBUHALER can be used according to three different treatment approaches: A. SYMBICORT TURBUHALER Anti-inflammatory Reliever Therapy: in patients with mild persistent asthma, SYMBICORT 200 TURBUHALER is taken as needed for relief of asthma symptoms when they occur. SYMBICORT TURBUHALER has not been evaluated in patients whose asthma can be managed by occasional use of a rapid onset, short duration, inhaled beta2-agonist. B. SYMBICORT TURBUHALER Anti-inflammatory Reliever plus Maintenance Therapy: in patients with moderate or severe asthma, SYMBICORT 100 TURBUHALER or SYMBICORT 200 TURBUHALER are taken both as daily maintenance therapy and as needed for relief of asthma symptoms when they occur. C. SYMBICORT TURBUHALER Maintenance Therapy: in patients with moderate or severe asthma, SYMBICORT TURBUHALER is taken as a fixed-dose daily COPYRIGHT 2002-2020 ASTRAZENEC… https://pdf.hres.ca/dpd_pm/00059997.PDF PM date: February 8, 2021 Source product: SYMBICORT 100 TURBUHALER; DIN 02245385; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.